Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Suven Life Sciences, a biopharmaceutical company, has received a product patent 4460446 from Japanese Patent Office (JPO), for its new chemical entity (NCE) that is used for the treatment of disorders associated with neurodegenerative diseases until 2023.
Subscribe to our email newsletter
Suven Life Sciences said that the granted claims of the patent include the class of selective serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents.
According to the invention 4460446 patent disclosure, the compounds are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), hungtinton’s disease, parkinson and schizophrenia.
Reportedly, there are several product patent applications from Suven Discovery Research in the pipiline and Suven secured intellectual property protection for several of its NCE’s in all major markets like US, Canada, China, Russia, India, Australia, New Zealand, Brazil and Mexico. These granted patents are exclusive intellectual property of Suven and are achieved through the internal drug discovery research efforts.
Venkat Jasti, CEO of Suven, said: “We are pleased by the grant of this patent to Suven by Japanese Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20bn market potential globally.”